2019
Impact of Chronic Kidney Disease on Outcomes in Cirrhosis
Wong F, Reddy K, O’Leary J, Tandon P, Biggins SW, Garcia‐Tsao G, Maliakkal BJ, Lai JC, Fallon MB, Vargas HE, Subramanian R, Thuluvath PJ, Kamath PS, Thacker L, Bajaj JS. Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. Liver Transplantation 2019, 25: 870-880. PMID: 30908855, PMCID: PMC11075743, DOI: 10.1002/lt.25454.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseKidney diseasePrevalence of CKDEnd-stage liver diseaseHospital clinical courseAcute kidney injuryChild-Pugh scoreChronic liver failureHigher serum creatinineGlomerular filtration rateHigh-risk groupNorth American ConsortiumCKD groupHospital courseKidney injuryRefractory ascitesNegative patientsOverall survivalPositive patientsSerum creatinineCirrhosis etiologyClinical courseHospital admissionHospitalized patientsLiver failure
2005
Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders†
Chainuvati S, Khalid S, Kancir S, Shea M, Edwards J, Sernyak M, Wongcharatrawee S, Garcia‐Tsao G. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders†. Journal Of Viral Hepatitis 2005, 13: 235-241. PMID: 16611189, DOI: 10.1111/j.1365-2893.2005.00681.x.Peer-Reviewed Original ResearchConceptsCompletion of therapyVirological responsePatient demographicsSubstance useAntiviral therapyMental illnessHepatitis C virus infectionLiver disease characteristicsC virus infectionNIH Consensus ConferenceType of therapyLiver clinicSVR ratesHCV RNAPositive patientsRelative contraindicationTherapy completionTreatment patternsLiver diseaseTreatment eligibilityDisease characteristicsPatient populationPoor adherenceVirus infectionConsensus conferenceMethotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis
Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, McCashland TM, Zetterman RK, Peters MG, Di Bisceglie AM, Benner KG, Kowdley KV, Carithers RL, Rosoff L, Garcia‐Tsao G, Boyer JL, Boyer TD, Martinez EJ, Bass NM, Lake JR, Barnes DS, Bonacini M, Lindsay KL, Mills AS, Markin RS, Rubin R, West AB, Wheeler DE, Contos MJ, Hofmann AF. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005, 42: 1184-1193. PMID: 16250039, DOI: 10.1002/hep.20897.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisUrsodeoxycholic acidVariceal bleedingBiliary cirrhosisTreatment failureSerum bilirubinHistological stagingCourse of PBCM2 body surface areaData Safety Monitoring BoardAMA-positive patientsReasons of futilityFailure of treatmentDevelopment of ascitesBody surface areaSafety monitoring boardEffect of methotrexateLiver transplantationPositive patientsMulticenter trialMedian periodMedian timeHistological progressionMonitoring boardDrug toxicity